Íomhá chlúdaigh

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria

Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Zornitsa Mitkova (Údar), Maria Dimitrova (Údar), Miglena Doneva (Údar), Konstantin Tachkov (Údar), Maria Kamusheva (Údar), Lyubomir Marinov (Údar), Nikolay Gerasimov (Údar), Dimitar Tcharaktchiev (Údar), Guenka Petrova (Údar)
Formáid:	LEABHAR
Foilsithe / Cruthaithe:	Frontiers Media S.A., 2022-11-01T00:00:00Z.
Ábhair:	article
Rochtain ar líne:	Connect to this object online.
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
de réir: Maria Kamusheva, et al.
Foilsithe / Cruthaithe: (2020)

Analysis Of Patients' Opinion Of Prescribed Medicines: A Questionnaire - Based Pilot Study In Bulgaria
de réir: Zornitsa Emilova Mitkova, et al.
Foilsithe / Cruthaithe: (2023)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
de réir: Konstantin Tachkov, et al.
Foilsithe / Cruthaithe: (2019)

Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria - A Pilot Comparative Study
de réir: Maria Kamusheva, et al.
Foilsithe / Cruthaithe: (2021)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
de réir: Konstantin Tachkov, et al.
Foilsithe / Cruthaithe: (2021)

Analysis of the Household and Health Care System Expenditures in Bulgaria
de réir: Zornitsa Mitkova, et al.
Foilsithe / Cruthaithe: (2021)

Review of medicine utilization for Parkinson's disease management: the Bulgarian perspective
de réir: Zornitsa Mitkova, et al.
Foilsithe / Cruthaithe: (2021)

BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS
de réir: Konstantin Tachkov, et al.
Foilsithe / Cruthaithe: (2019)

Adherence to Acromegaly Treatment and Analysis of the Related Factors-A Real-World Study in Bulgaria
de réir: Maria Kamusheva, et al.
Foilsithe / Cruthaithe: (2023)

Incretins and SGLT-2i Therapy of Type 2 Diabetes - Real Life Study of Their Therapeutic and Economic Effects
de réir: Zornitsa Mitkova, et al.
Foilsithe / Cruthaithe: (2019)

Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
de réir: Stephanie Karanyotova, et al.
Foilsithe / Cruthaithe: (2023)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
de réir: Oksana Tkachova, et al.
Foilsithe / Cruthaithe: (2019)

Evaluating potentially inappropriate medications in elderly patients in a pharmacy setting in Bulgaria: A pilot study utilizing the EU (7)-PIM List
de réir: Petya Milushewa, et al.
Foilsithe / Cruthaithe: (2023)

Digital health in Bulgaria: Imagination or possible reality?
de réir: Maria Dimitrova, et al.
Foilsithe / Cruthaithe: (2023)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
de réir: Vladimira V. Boyadzieva, et al.
Foilsithe / Cruthaithe: (2018)

Proton therapy for head and neck cancer therapy: A real-world data case study from Bulgaria
de réir: Maria Dimitrova, et al.
Foilsithe / Cruthaithe: (2024)

Cost-effectiveness of treatment intervention in prediabetic patients in Bulgaria
de réir: Stanislava Yordanova, et al.
Foilsithe / Cruthaithe: (2023)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
de réir: Maria Kamusheva, et al.
Foilsithe / Cruthaithe: (2018)

The Impact of Global Budgets on Pharmaceutical Spending and Utilization
de réir: Christopher C. Afendulis PhD, et al.
Foilsithe / Cruthaithe: (2014)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
de réir: Maria Kamusheva, et al.
Foilsithe / Cruthaithe: (2021)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
de réir: Vera Stoeva, et al.
Foilsithe / Cruthaithe: (2023)

HEALTH SERVICES CONSUMPTION AND BARRIERS IN THE HEALTH CARE OF PERSONS OF ROMA ORIGIN IN BULGARIA
de réir: Mariela Kambouraova, et al.
Foilsithe / Cruthaithe: (2024)

Predicting the outcomes and costs for a cohort of 426 patients with Chronic Obstructive Pulmonary Disease (COPD) in Bulgaria through a Markov model
de réir: Konstantin Tachkov, et al.
Foilsithe / Cruthaithe: (2019)

Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases-STOPP/START-based study
de réir: Tzvetan Krustev, et al.
Foilsithe / Cruthaithe: (2022)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
de réir: Konstantin Tachkov, et al.
Foilsithe / Cruthaithe: (2022)

ANALYSIS OF USAGE AND QUALITY OF WILD EDIBLE MUSHROOMS BY PEOPLE FROM BULGARIA, COMPARED TO OTHER FOREIGN COUNTRIES
de réir: Tsonka Dimitrova, et al.
Foilsithe / Cruthaithe: (2021)

Impact of Polypharmacy, Drug-Related Problems, and Potentially Inappropriate Medications in Geriatric Patients and Its Implications for Bulgaria-Narrative Review and Meta-Analysis
de réir: Tzvetan Krustev, et al.
Foilsithe / Cruthaithe: (2022)

Pharmacists' attitudes to dispensing food supplements to chronically ill patients: a pilot survey among community pharmacies in Bulgaria
de réir: Antoaneta Balkanska-Mitkova, et al.
Foilsithe / Cruthaithe: (2022)

COVID-19 pandemic impact on the pharmaceutical sector in Bulgaria
de réir: Veselina Ivanova, et al.
Foilsithe / Cruthaithe: (2021)

Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in Bulgaria
de réir: Georgi eIskrov, et al.
Foilsithe / Cruthaithe: (2015)

VITAMIN D STATUS AND DIETARY HABITS OF CHILDREN WITH ADOLESCENT IDIOPATHIC SCOLIOSIS IN VARNA
de réir: Dimitar B. Marinov, et al.
Foilsithe / Cruthaithe: (2021)

Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan
de réir: Dana Dadanbekova, et al.
Foilsithe / Cruthaithe: (2024)

Quality of life of patients with cardiomyopathy treated with sacubitril/valsartan vs. standard therapy during or after COVID-19 in Kazakhstan
de réir: Dana Dadanbekova, et al.
Foilsithe / Cruthaithe: (2024)

Tuberculosis in Adolescents in Bulgaria for a Three-Year Period: 2018-2020
de réir: Natalia Gabrovska, et al.
Foilsithe / Cruthaithe: (2022)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
de réir: Maria Dimitrova, et al.
Foilsithe / Cruthaithe: (2022)

EATING HABITS AND BEHAVIOR IN ADOLESCENTS FROM DIFFERENT ETHNIC GROUPS IN THE MUNICIPALITY OF PLOVDIV, BULGARIA
de réir: Gergana Petrova, et al.
Foilsithe / Cruthaithe: (2022)

PREVALENCE OF CARIES AND THE NEED FOR URGENT DENTAL TREATMENT AMONG CHILDREN WITH NEUROLOGICAL IMPAIRMENT IN NORTHEASTERN BULGARIA
de réir: Rouzha Pancheva, et al.
Foilsithe / Cruthaithe: (2023)

COVID-19 AND REGIONAL HEALTH INEQUALITIES IN BULGARIA
de réir: Dima Tsanova, et al.
Foilsithe / Cruthaithe: (2024)

IMPLEMENTATION OF EU DIRECTIVES FOR CERTIFICATION OF THE STAFF IN THE SPA BUSINESS IN BULGARIA
de réir: Petya Kutincheva, et al.
Foilsithe / Cruthaithe: (2013)

Adherence to disease-modifying therapies among patients with multiple sclerosis in Bulgaria - A real world study
de réir: Yoana Seitaridou, et al.
Foilsithe / Cruthaithe: (2024)